United Statesallianceforclinicaltrialsinoncology.org
Alliance for Clinical Trials in Oncology (Alliance) is a U.S.-based, National Cancer Institute–supported cooperative research group that designs, conducts, and analyzes multicenter clinical trials in cancer. Working across a large network of academic and community hospitals, the Alliance runs phase I–III studies spanning a wide range of tumor types and clinical settings.
The group evaluates chemotherapies, targeted agents, biologics, and immunotherapies—often with biomarker-driven and translational components—to assess efficacy, safety, and optimal use of novel and established treatments. Through partnerships with member institutions and industry sponsors, its trials generate pivotal evidence that informs standards of care, regulatory decisions, and clinical guidelines. Alliance research infrastructure supports rigorous data management and specimen-based investigations, providing decision-grade insights relevant to pharmaceutical and biotechnology development in oncology.
Filing in Japan for adjuvant treatment of MSI‑High colon cancer after Phase III ATOMIC showed reduced recurrence risk and improved 3‑year DFS.
FDA accepted an sBLA for adjuvant PD‑L1 therapy plus chemotherapy in stage III dMMR/MSI‑H colon cancer; agency decision expected Oct 9, 2026.
Roche presents over 30 abstracts on cancer treatments, including breast, lung, and bladder cancers, at ESMO 2025, showcasing significant advancements in progression-free and overall survival.